Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
181-200 of 847 trials

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Preclinical Alzheimer's Disease: JNJ-64042056 Immunotherapy

We are studying a new treatment to see if it may help slow cognitive decline in people with preclinical Alzheimer's disease. Participants will receive either the treatment or a placebo to compare effects.

Preclinical Alzheimer's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

We are comparing a new treatment, bomedemstat, to hydroxyurea in people with essential thrombocythemia who haven't been treated before. The goal is to see which treatment better reduces symptoms and fatigue.

Essential Thrombocythemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHematology

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Hidradenitis Suppurativa: Bimekizumab for Teens

We are studying how the drug bimekizumab works and its safety for treating moderate to severe hidradenitis suppurativa in pubertal children and adolescents.

Hidradenitis SuppurativaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyDermatology

Myotonic Dystrophy Type 1: ATX-01 Treatment Study

We are evaluating the safety and effects of ATX-01 in adults with myotonic dystrophy type 1. The study aims to see how it impacts muscle function and daily living activities.

Myotonic Dystrophy6-12 monthsSafety phase (I)Post-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Metastatic Colorectal Cancer: LB-100 and Atezolizumab Study

We are investigating a new combination of medications for patients with metastatic colorectal cancer to see if it is safe and effective. This study aims to find the best dose and understand how well the treatment works.

Microsatellite Stable Colorectal Cancer>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology